MX365663B - Solucion de atomoxetina. - Google Patents

Solucion de atomoxetina.

Info

Publication number
MX365663B
MX365663B MX2016005998A MX2016005998A MX365663B MX 365663 B MX365663 B MX 365663B MX 2016005998 A MX2016005998 A MX 2016005998A MX 2016005998 A MX2016005998 A MX 2016005998A MX 365663 B MX365663 B MX 365663B
Authority
MX
Mexico
Prior art keywords
atomoxetine
aqueous solution
atomoxetine solution
solution
swallow
Prior art date
Application number
MX2016005998A
Other languages
English (en)
Spanish (es)
Other versions
MX2016005998A (es
Inventor
S Mermey Matthew
Kumar Roy Arup
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49920679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX365663(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016005998A publication Critical patent/MX2016005998A/es
Publication of MX365663B publication Critical patent/MX365663B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016005998A 2013-11-08 2013-12-19 Solucion de atomoxetina. MX365663B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361901577P 2013-11-08 2013-11-08
PCT/US2013/076435 WO2014204513A1 (en) 2013-11-08 2013-12-19 Atomoxetine solution

Publications (2)

Publication Number Publication Date
MX2016005998A MX2016005998A (es) 2016-07-18
MX365663B true MX365663B (es) 2019-06-10

Family

ID=49920679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005998A MX365663B (es) 2013-11-08 2013-12-19 Solucion de atomoxetina.

Country Status (15)

Country Link
US (1) US9326935B2 (enExample)
EP (1) EP2838510B1 (enExample)
JP (1) JP5973073B2 (enExample)
CN (1) CN105705135A (enExample)
CY (1) CY1118100T1 (enExample)
DK (1) DK2838510T3 (enExample)
ES (1) ES2605495T3 (enExample)
HU (1) HUE032205T2 (enExample)
IL (1) IL244878A (enExample)
MX (1) MX365663B (enExample)
PL (1) PL2838510T3 (enExample)
PT (1) PT2838510T (enExample)
SI (1) SI2838510T1 (enExample)
TW (1) TWI583402B (enExample)
WO (1) WO2014204513A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726473A (zh) * 2016-03-31 2016-07-06 北京万全德众医药生物技术有限公司 托莫西汀或其可药用盐口服溶液及其制备方法
CN106727291B (zh) * 2016-12-06 2020-02-11 山东达因海洋生物制药股份有限公司 一种盐酸托莫西汀口服溶液及其制备方法
US9855228B1 (en) * 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof
CN111437247A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种托莫西汀口服液的制备方法
CN112438949A (zh) * 2019-09-05 2021-03-05 北京兴源联合医药科技有限公司 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法
CN112451476A (zh) * 2019-09-09 2021-03-09 北京兴源联合医药科技有限公司 一种盐酸托莫西汀口服液及其制备方法
CN111956607A (zh) * 2020-09-25 2020-11-20 健民药业集团股份有限公司 盐酸托莫西汀口服溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ198953A (en) * 1980-11-14 1984-10-19 Lilly Co Eli (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
CA2400571A1 (en) * 2000-03-07 2001-09-13 Eli Lilly And Company Treatment of psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
CA2600609A1 (en) * 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
CN101155775A (zh) * 2005-04-05 2008-04-02 特瓦药物精化学品股份有限公司 稳定的阿托莫西汀盐酸盐、其制备方法，以及其稳定性分析控制
US20070134277A1 (en) * 2005-12-09 2007-06-14 Children's Medical Center Corporation Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20080031932A1 (en) 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20080145318A1 (en) 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
US9629920B2 (en) * 2009-12-18 2017-04-25 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
WO2011123695A1 (en) 2010-03-31 2011-10-06 Abela Pharmaceuticals, Inc. Dimethy sulfoxxide (dmso) formulations for treating autism
JP6336902B2 (ja) 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US20120128683A1 (en) 2011-11-22 2012-05-24 Shantha Totada R Autism treatment

Also Published As

Publication number Publication date
IL244878A0 (en) 2016-05-31
TWI583402B (zh) 2017-05-21
WO2014204513A1 (en) 2014-12-24
TW201431567A (zh) 2014-08-16
US20150133562A1 (en) 2015-05-14
PT2838510T (pt) 2016-11-23
CN105705135A (zh) 2016-06-22
CY1118100T1 (el) 2017-06-28
US9326935B2 (en) 2016-05-03
IL244878A (en) 2017-04-30
ES2605495T3 (es) 2017-03-14
JP5973073B2 (ja) 2016-08-23
SI2838510T1 (sl) 2016-11-30
JP2015522624A (ja) 2015-08-06
DK2838510T3 (en) 2016-12-19
HUE032205T2 (en) 2017-09-28
PL2838510T3 (pl) 2017-09-29
MX2016005998A (es) 2016-07-18
EP2838510B1 (en) 2016-09-21
EP2838510A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MX365663B (es) Solucion de atomoxetina.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
PH12016500433B1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
IL273740A (en) Oral pharmaceutical formulation containing bacteria
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
BR112014000347A2 (pt) método para melhorar o aroma de um alimento, bebida, produto farmacêutico ou produto para o cuidado oral, e, alimento, bebida, produto farmacêutico ou produto para o cuidado oral
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
MX368117B (es) Modulador de sabor y metodo para utilizar el mismo.
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
IN2014DN09240A (enExample)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
EP3141264A4 (en) Pharmaceutical preparation for masked taste oral administration, containing clomipramine
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
MD4291B1 (ro) Preparat medicamentos pentru tratamentul otitelor
UA103542U (ru) Настойка горька "таврийские мечты"
UA88471U (ru) Лекарственное средство в форме перорального раствора для лечения заболеваний органов пищеварения
MX366763B (es) Composiciones farmacéuticas de montelukast y levocetirizina.
EA200900174A1 (ru) Фармацевтическая композиция для лечения желудочных расстройств
EA201101708A1 (ru) Фармацевтическая композиция для лечения желудочных расстройств
IN2013MU04101A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration